Metabolic Therapy as an Adjunct to Conventional Cancer Treatment:A Targeted Approach
DOI:
https://doi.org/10.37506/m5t0j192Keywords:
Metabolic therapy; , metabolic inhibitors, dietary interventions; , natural compounds; , metabolic regulators.Abstract
Context: Metabolic therapy encompasses a range of strategies that involve the utilization of metabolic inhibitors,
dietary interventions, and natural compounds that modulate metabolic regulators. These methodologies exhibit
promising outcomes in preclinical models and early-phase clinical trials for cancer treatment.
Objectives: To elucidate how metabolic therapy disrupts energy production in neoplastic cells while protecting
normal cells.
Methods: A comprehensive literature review was conducted utilizing scientific databases.
Results: Metabolic therapy targets cancer cells’ energy pathways with inhibitors like metformin and dichloroacetate,
disrupting growth without harming normal cells. Dietary strategies, including the ketogenic diet, starve cancer cells
and promote fat consumption. Natural compounds like curcumin and resveratrol regulate metabolic processes in
cancer cells, potentially slowing tumor growth.
Discussion: Clinical trials have demonstrated encouraging outcomes with the implementation of metabolic
therapies.
Conclusion: Strategic exploitation of metabolic vulnerabilities in cancer cells offers a promising avenue for
effective therapeutic interventions in the battle against cancer.
References
1. Longo VD, Brandhorst S. Fasting and caloric restriction in cancer prevention and treatment. Recent Results Cancer Res 2016;241–266.
2. Warburg O. On the origin of cancer cells. Science 1956; 123:309–314.
3. Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014; 35:515–527.
4. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab 2010; 7:7.
5. Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM. Emerging therapies in cancer. Cell Metab 2023; 35:1283–1303.
6. Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol 2024; 13:10.
7. Klement RJ, Champ CE. Calories, carbohydrates, and radiation therapy: exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev 2014; 33:217–229.
8. Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discov 2016; 6:1315–1333.
9. Pollak M. Metformin and other biguanides in oncology. Cancer Prev Res 2010; 3:1060–1065.
10. Michelakis ED, Webster L, Mackey JR. Dichloroacetate as a metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989–994.
11. Pajak B, Siwiak E, Sołtyka M, et al. 2-Deoxy-D-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci 2019; 21:234.
12. Zhu H, Bi D, Zhang Y, et al. Ketogenic diet for human diseases: underlying mechanisms and clinical potential. Signal Transduct Target Ther 2022; 7:11.
13. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in cancer treatment. Mol Metab 2020; 33:102–121.
14. Talib WH, Mahmod AI, Kamal A, et al. Ketogenic diet in cancer prevention and therapy. Curr Issues Mol Biol 2021; 43:558–589.
15. Longo VD, Brandhorst S. Fasting and caloric restriction for reducing tumor growth. Recent Results Cancer Res 2016; 207:241–266.
16. Shanmugam MK, Rane G, Kanchi MM, et al. Multifaceted role of curcumin in cancer. Molecules 2015; 20:2728–2769.
17. Siddiqui FA, Prakasam G, Chattopadhyay S, et al. Curcumin reduces the Warburg effect via PKM2 and mTOR-HIF1α inhibition. Sci Rep 2018; 8:8323.
18. Ko JH, Um JY, Shanmugam MK, et al. The role of resveratrol in cancer therapy. Int J Mol Sci 2017; 18:2589.
19. Seyfried TN, Chinopoulos C. Mitochondrial metabolic theory vs. somatic mutation theory. Metabolites 2021; 11:572.
20. Seyfried TN, Shivane AG, Kalamian M, Maroon J, Mukherjee P, Zuccoli G. Ketogenic metabolic therapy for IDH1-mutant glioblastoma: case report. Front Nutr 2021; 8:682243.
21. Fadaka A, Ajiboye B, Ojo O, et al. Glucose metabolism in cancer. J Oncol Sci 2017; 3:45–51.
22. Sayad A. Biochemical origin of the Warburg effect. Onco Targets Ther 2023; 16:143–155.
23. Chen XS, Li LY, Guan YD, Yang JM, Cheng Y. Targeting the Warburg effect. Acta Pharmacol Sin 2016; 37:1013–1019.
24. Pavlova NN, Thompson CB. Emerging hallmarks of cancer metabolism. Cell Metab 2016, 23:27–47.
25. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: therapeutic perspective. Nat Rev Clin Oncol 2017; 14:11–31.
26. Batis N, Brooks JM, Payne K, et al. Lack of predictive tools for targeted therapy. Adv Drug Deliv Rev 2021; 176:113854.
27. Faubert B, Solmonson A, De Berardinis R J. Metabolic reprogramming and cancer progression. Science 2020; 368:eaaw5473.
28. Maschek G, Savaraj N, Priebe W, et al. 2-DG increases the efficacy of Adriamycin and paclitaxel. Cancer Res 2004;64:31–34.
29. Allen BG, Bhatia SK, Anderson CM, et al. Ketogenic diets as adjuvant cancer therapy. Redox Biol 2014; 2:963–970.
30. Lyssiotis CA, Kimmelman CA. Metabolic interactions in the tumor microenvironment. Trends Cell Biol 2017; 27:863–875.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Madhu Bala, Jyoti Kaur
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Ownership: Authors retain copyright ownership of their work after publication in IJOP. However, they grant the journal an exclusive Creative Commons license.
Creative Commons License: The authors grant IJOP the right to exclusively apply a Creative Commons license to their work upon publication. This license permits use, distribution, and reproduction of the work in any medium, provided that the original work and its source are properly cited. The specific license applied is Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which allows for attribution, non-commercial use, and derivative works.
Editorial Research: Authors grant the journal the right to analyze information obtained from submitted manuscripts for editorial research purposes. This analysis aims to improve the peer-review process, teaching, and training activities.
Warranties: Authors warrant that their work is original, contains no libelous statements, is lawful, and does not infringe upon any copyright, trademark, patent, or proprietary rights of others. Authors agree to indemnify the editors against any costs, expenses, and damages arising from any breach of this warranty.
Views and Opinions: The views and opinions expressed in the article are those of the authors and not necessarily those of the journal.